公开(公告)号：US20090186047A1

公开(公告)日：2009-07-23

申请号：US12298509

申请日：2006-04-25

申请人： Alexander Von Gabain ,  Katherine Cohen ,  Karen Lingnau ,  Michael Ginzler ,  Erich Tauber ,  Christoph Klade ,  Alessandra Formica ,  Wolfgang Zauner

发明人： Alexander Von Gabain ,  Katherine Cohen ,  Karen Lingnau ,  Michael Ginzler ,  Erich Tauber ,  Christoph Klade ,  Alessandra Formica ,  Wolfgang Zauner

IPC分类号： A61K39/29

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  C07K14/005 ,  C12N2770/24222 ,  C12N2770/24234

摘要： The invention relates to a method for preventing or treating Hepatitis C Virus (HCVi) infections, wherein a HCV vaccine comprising an effective amount of at least one HCV T-cell antigen and a polycationic compound comprising peptide bonds is administered to a human individual bi-weekly at least 3 times.

摘要翻译： 本发明涉及一种预防或治疗丙型肝炎病毒（HCVi）感染的方法，其中包含有效量的至少一种HCV T细胞抗原和包含肽键的聚阳离子化合物的HCV疫苗被施用于人类个体双 - 每周至少3次。

公开(公告)号：US20130034575A1

公开(公告)日：2013-02-07

申请号：US13613761

申请日：2012-09-13

申请人： Andreas Meinke ,  Eszter Nagy ,  Uwe Von Ahsen ,  Christoph Klade ,  Tamas Henics ,  Wolfgang Zauner ,  Duc Bui Minh ,  Oresta Vytvytska ,  Hildegard Etz ,  Agnieszka Dryla ,  Thomas Weichhart ,  Martin Hafner ,  Brigitte Tempelmaier ,  Claire M. Fraser ,  Steven Gill

发明人： Andreas Meinke ,  Eszter Nagy ,  Uwe Von Ahsen ,  Christoph Klade ,  Tamas Henics ,  Wolfgang Zauner ,  Duc Bui Minh ,  Oresta Vytvytska ,  Hildegard Etz ,  Agnieszka Dryla ,  Thomas Weichhart ,  Martin Hafner ,  Brigitte Tempelmaier ,  Claire M. Fraser ,  Steven Gill

IPC分类号： A61K39/00 ,  C07K16/00 ,  C07K7/08 ,  C07K14/00 ,  C07K7/06

CPC分类号： C40B40/02 ,  A61K39/00 ,  C07K14/195 ,  C07K14/31 ,  C07K16/1271 ,  C12N15/1037 ,  C12N15/1041 ,  C12Q1/6806 ,  Y02A50/401 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472 ,  Y02A50/52 ,  Y02A50/54 ,  Y02A50/57 ,  C12Q2527/125 ,  C12Q2521/537

摘要： Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

摘要翻译： 描述了一种鉴定，分离和产生来自特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主的超免疫血清反应性抗原的方法，所述抗原适用于给定类型的疫苗 其特征在于以下步骤：提供抗体制剂，提供至少一种表达文库，鉴定结合筛选鉴定的抗原的抗原，鉴定所述鉴定的抗原的超免疫血清反应性抗原部分，以及哪些 超免疫血清反应性抗原结合所述单独抗体的相关部分，任选分离所述超免疫血清反应性抗原，并通过化学或重组方法产生所述超免疫血清反应性抗原。

公开(公告)号：US20120308618A1

公开(公告)日：2012-12-06

申请号：US13578686

申请日：2011-02-21

申请人： Benjamin Wizel ,  Karin Riedl ,  Karen Lingnau ,  Ursula Schlosser ,  Jürgen Wruss ,  Robert Schlegl ,  Michael Weber ,  Christoph Reinisch ,  Ljubomir Paucz ,  Christoph Klade ,  Jee Loon Look ,  Christian Ruiz ,  Robert Seid

发明人： Benjamin Wizel ,  Karin Riedl ,  Karen Lingnau ,  Ursula Schlosser ,  Jürgen Wruss ,  Robert Schlegl ,  Michael Weber ,  Christoph Reinisch ,  Ljubomir Paucz ,  Christoph Klade ,  Jee Loon Look ,  Christian Ruiz ,  Robert Seid

IPC分类号： A61K39/39 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P33/00 ,  A61P33/02 ,  A61P31/04 ,  A61P31/10 ,  A61K9/14 ,  A61P31/22

CPC分类号： A61K39/39 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14 ,  A61K9/51 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/092 ,  A61K39/118 ,  A61K39/12 ,  A61K39/145 ,  A61K39/40 ,  A61K39/42 ,  A61K48/00 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/70 ,  C12N7/00 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2760/16234 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/396 ,  Y02A50/401 ,  Y02A50/412 ,  Y02A50/47

摘要： The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 μm.

摘要翻译： 本发明公开了液体形式的药物组合物，其包含具有氨基酸序列KLKL5KLK的肽和具有核酸序列（dIdC）13的寡脱氧核苷酸的肽，并且其中肽和寡脱氧核苷酸作为无菌可过滤纳米粒子存在于组合物中，由此形成 悬浮液，其特征在于固体颗粒的平均粒径小于1μm。

公开(公告)号：US20090060875A1

公开(公告)日：2009-03-05

申请号：US11577798

申请日：2005-09-23

申请人： Jurgen Frisch ,  Erich Tauber ,  Vera Burger ,  Christoph Klade ,  Michael Buschle ,  Katherine Cohen

发明人： Jurgen Frisch ,  Erich Tauber ,  Vera Burger ,  Christoph Klade ,  Michael Buschle ,  Katherine Cohen

IPC分类号： A61K38/21 ,  A61K39/00 ,  A61P31/00 ,  A61K38/00

CPC分类号： C07K14/005 ,  A61K39/39 ,  A61K2039/55 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/57 ,  C12N2770/24222

摘要： The invention discloses the use of polycationic compounds for the preparation and manufacturing of medicaments, pharmaceutical compositions, especially vaccines for the treatment of patients with HCV chronic infections.

摘要翻译： 本发明公开了用于制备和制备药物，药物组合物，特别是用于治疗HCV慢性感染患者的疫苗的聚阳离子化合物的用途。

公开(公告)号：US20080038287A1

公开(公告)日：2008-02-14

申请号：US11614716

申请日：2006-12-21

申请人： Andreas Meinke ,  Eszter Nagy ,  Uwe Von Ahsen ,  Christoph Klade ,  Tamas Henics ,  Wolfgang Zauner ,  Duc Minh ,  Oresta Vytvytska ,  Hildegard Etz ,  Agnieszka Dryla ,  Thomas Weichhart ,  Martin Hafner ,  Brigitte Tempelmaier ,  Claire Fraser ,  Steven Gill

发明人： Andreas Meinke ,  Eszter Nagy ,  Uwe Von Ahsen ,  Christoph Klade ,  Tamas Henics ,  Wolfgang Zauner ,  Duc Minh ,  Oresta Vytvytska ,  Hildegard Etz ,  Agnieszka Dryla ,  Thomas Weichhart ,  Martin Hafner ,  Brigitte Tempelmaier ,  Claire Fraser ,  Steven Gill

IPC分类号： A61K39/00 ,  A61P43/00 ,  C07K14/00 ,  C07K16/18 ,  C12N15/00 ,  C12P21/04 ,  C12Q1/68 ,  G01N33/53

CPC分类号： C40B40/02 ,  A61K39/00 ,  C07K14/195 ,  C07K14/31 ,  C07K16/1271 ,  C12N15/1037 ,  C12N15/1041 ,  C12Q1/6806 ,  Y02A50/401 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472 ,  Y02A50/52 ,  Y02A50/54 ,  Y02A50/57 ,  C12Q2527/125 ,  C12Q2521/537

摘要： Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: —providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —screening said at least one expression library with said antibody preparation, —identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and —optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

摘要翻译： 描述了用于鉴定，分离和产生来自特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主的超免疫血清反应性抗原的方法，所述抗原适用于给定类型动物的疫苗 其特征在于以下步骤： - 从所述给定类型的动物的血浆池或从具有针对所述特异性病原体，肿瘤，变应原或组织或宿主的抗体的人血浆池或个体血清提供抗体制剂 易于自身免疫，提供易于自身免疫的所述特异性病原体，肿瘤，变应原或组织或宿主的至少一个表达文库， - 用所述抗体制剂筛选所述至少一种表达文库， - 鉴定结合于 对所述抗体制剂中的抗体进行筛选，用来自具有抗体a的个体的来自个体血清的各抗体制剂筛选鉴定的抗原 所述特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主，鉴定所述鉴定的抗原的超免疫血清反应性抗原部分，哪些超免疫血清反应性抗原与所述单个抗体制剂的相关部分结合来自所述 单独血清，并且通过化学或重组方法选择性分离所述超免疫血清反应性抗原并产生所述超免疫血清反应性抗原。

公开(公告)号：US08323660B2

公开(公告)日：2012-12-04

申请号：US12853074

申请日：2010-08-09

申请人： Andreas Meinke ,  Eszter Nagy ,  Uwe Von Ahsen ,  Christoph Klade ,  Tamas Henics ,  Wolfgang Zauner ,  Duc Bui Minh ,  Oresta Vytvytska ,  Hildegard Etz ,  Agnieszka Dryla ,  Thomas Weichhart ,  Martin Hafner ,  Brigitre Tempelmaier ,  Claire M. Fraser ,  Steven Gill

发明人： Andreas Meinke ,  Eszter Nagy ,  Uwe Von Ahsen ,  Christoph Klade ,  Tamas Henics ,  Wolfgang Zauner ,  Duc Bui Minh ,  Oresta Vytvytska ,  Hildegard Etz ,  Agnieszka Dryla ,  Thomas Weichhart ,  Martin Hafner ,  Brigitre Tempelmaier ,  Claire M. Fraser ,  Steven Gill

IPC分类号： A61K39/085

CPC分类号： C40B40/02 ,  A61K39/00 ,  C07K14/195 ,  C07K14/31 ,  C07K16/1271 ,  C12N15/1037 ,  C12N15/1041 ,  C12Q1/6806 ,  Y02A50/401 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472 ,  Y02A50/52 ,  Y02A50/54 ,  Y02A50/57 ,  C12Q2527/125 ,  C12Q2521/537

摘要： Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation,—identifying antigens which bind in said screening to antibodies in said antibody preparation,—screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and—optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

摘要翻译： 描述了用于鉴定，分离和产生来自特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主的超免疫血清反应性抗原的方法，所述抗原适用于给定类型动物的疫苗 其特征在于以下步骤： - 从所述给定类型的动物的血浆池或从具有针对所述特异性病原体，肿瘤，变应原或组织或宿主的抗体的人血浆池或个体血清提供抗体制剂 易于自身免疫，提供易于自身免疫的所述特异性病原体，肿瘤，变应原或组织或宿主的至少一个表达文库， - 用所述抗体制剂筛选所述至少一种表达文库， - 鉴定结合于 对所述抗体制剂中的抗体进行筛选，用来自具有抗体的个体的来自个体血清的单独抗体制剂筛选鉴定的抗原 针对所述特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主， - 鉴定所述鉴定的抗原的超免疫血清反应性抗原部分，哪些超免疫血清反应性抗原与所述单个抗体制剂的相关部分结合 所述个体血清和任选地分离所述超免疫血清反应性抗原并通过化学或重组方法产生所述超免疫血清反应性抗原。

公开(公告)号：US07968297B2

公开(公告)日：2011-06-28

申请号：US10470048

申请日：2002-01-21

申请人： Andreas Meinke ,  Eszter Nagy ,  Uwe Von Ahsen ,  Christoph Klade ,  Tamas Henics ,  Wolfgang Zauner ,  Duc Bui Minh ,  Oresta Vytvytska ,  Hildegard Etz ,  Agnieszka Dryla ,  Thomas Weichhart ,  Martin Hafner ,  Brigitte Tempelmaier ,  Claire M. Fraser ,  Steven Gill

发明人： Andreas Meinke ,  Eszter Nagy ,  Uwe Von Ahsen ,  Christoph Klade ,  Tamas Henics ,  Wolfgang Zauner ,  Duc Bui Minh ,  Oresta Vytvytska ,  Hildegard Etz ,  Agnieszka Dryla ,  Thomas Weichhart ,  Martin Hafner ,  Brigitte Tempelmaier ,  Claire M. Fraser ,  Steven Gill

IPC分类号： G01N33/53

CPC分类号： C40B40/02 ,  A61K39/00 ,  C07K14/195 ,  C07K14/31 ,  C07K16/1271 ,  C12N15/1037 ,  C12N15/1041 ,  C12Q1/6806 ,  Y02A50/401 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472 ,  Y02A50/52 ,  Y02A50/54 ,  Y02A50/57 ,  C12Q2527/125 ,  C12Q2521/537

摘要： Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: —providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —screening said at least one expression library with said antibody preparation, —identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and —optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

摘要翻译： 描述了用于鉴定，分离和产生来自特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主的超免疫血清反应性抗原的方法，所述抗原适用于给定类型动物的疫苗 其特征在于以下步骤： - 从所述给定类型的动物的血浆池或从具有针对所述特异性病原体，肿瘤，变应原或组织或宿主的抗体的人血浆池或个体血清提供抗体制剂 易于自身免疫，提供易于自身免疫的所述特异性病原体，肿瘤，变应原或组织或宿主的至少一个表达文库， - 用所述抗体制剂筛选所述至少一种表达文库， - 鉴定结合于 对所述抗体制剂中的抗体进行筛选， - 用来自个体的个体血清筛选鉴定的抗原与单独的抗体制剂 针对所述特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主的抗体， - 鉴定所述鉴定的抗原的超免疫血清反应性抗原部分，哪些超免疫血清反应性抗原结合所述单个抗体制剂的相关部分 所述个体血清和 - 通过化学或重组方法选择性分离所述超免疫血清反应性抗原并产生所述超免疫血清反应性抗原。

公开(公告)号：US20090155294A1

公开(公告)日：2009-06-18

申请号：US12248587

申请日：2008-10-09

申请人： MICHAEL BUSCHLE ,  JURGEN FRISCH ,  CHRISTOPH KLADE ,  KAREN LINGNAU ,  WOLFGANG ZAUNER ,  GERD ZETTLMEISSL

发明人： MICHAEL BUSCHLE ,  JURGEN FRISCH ,  CHRISTOPH KLADE ,  KAREN LINGNAU ,  WOLFGANG ZAUNER ,  GERD ZETTLMEISSL

IPC分类号： A61K39/29

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/55516 ,  A61K2039/55561 ,  C12N2770/24222 ,  C12N2770/24234

摘要： Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided.

公开(公告)号：US20090130135A1

公开(公告)日：2009-05-21

申请号：US12248744

申请日：2008-10-09

申请人： MICHAEL BUSCHLE ,  JURGEN FRISCH ,  CHRISTOPH KLADE ,  KAREN LINGNAU ,  WOLFGANG ZAUNER ,  GERD ZETTLMEISSL

发明人： MICHAEL BUSCHLE ,  JURGEN FRISCH ,  CHRISTOPH KLADE ,  KAREN LINGNAU ,  WOLFGANG ZAUNER ,  GERD ZETTLMEISSL

IPC分类号： A61K39/29

CPC分类号： A61K39/29 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55561 ,  A61K2039/57 ,  C07K14/005 ,  C12N2770/24222 ,  C12N2770/24234

摘要： Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided.

摘要翻译： 公开了用于诱导针对丙型肝炎病毒（HCV）的免疫应答的方法和组合物。 组合物包含来自热点表位的一个或多个表位。 在某些实施方案中，提供了包含至少两个表位的HCV疫苗，每个表位各自为不同的热点表位。

公开(公告)号：US20070031446A1

公开(公告)日：2007-02-08

申请号：US10564429

申请日：2004-07-09

申请人： Michael Buschle ,  Jurgen Frisch ,  Christoph Klade ,  Karen Lingnau ,  Wolfgang Zauner ,  Gerd Zettlmeissl

发明人： Michael Buschle ,  Jurgen Frisch ,  Christoph Klade ,  Karen Lingnau ,  Wolfgang Zauner ,  Gerd Zettlmeissl

IPC分类号： A61K39/29 ,  C07K14/18

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/55516 ,  A61K2039/55561 ,  C12N2770/24222 ,  C12N2770/24234

摘要： Disclosed is a Hepatitis C virus (HCV) vaccine comprising at least two epitopes, each from a different hotspot epitope, wherein a hotspot epitope is defined as an epitope containing peptide selected from the group consisting of KFPGGGQIVGGVYLLPRRGPRLGVRATRK, GYKVLVLNPSVAAT, AYAAQGYKVLVLNPSVAAT, DLMGYIP(A/L)VGAPL, GEVQVVSTATQSFLATCINGVCWTV, HMWNFISGIQYLAGLSTLPGNPA, VDYPYRLWHYPCT(V/I)N(F/Y)TIFK(V/I)RMYVGGVEHRL, AAWYELTPAETTVRLR, GQGWRLLAPITAYSQQTRGLLGCIV, IGLGKVLVDILAGYGAGVAGALVAFK, FTDNSSPPAVPQTFQV, LEDRDRSELSPLLLSTTEW, YLVAYQATVCARAQAPPPSWD, MSTNPKPQRKTKRNTNR, LINTNGSWHINRTALNCNDSL, TTILGIGTVLDQAET, FDS(S/V)VLCECYDAG(A/C)AWYE, ARLIVFPDLGVRVCEKMALY, AFCSAMYVGDLCGSV, GVLFGLAYFSMVGNW, VVCCSMSYTWTGALITPC, TRVPYFVRAQGLIRA and TTLLFNILGGWVAAQ.

摘要翻译： 公开了一种丙型肝炎病毒（HCV）疫苗，其包含至少两个表位，每个表位各自为不同的热点表位，其中热点表位定义为选自KFPGGGQIVGGVYLLPRRGPRLGVRATRK，GYKVLVLNPSVAAT，AYAAQGYKVLVLNPSVAAT，DLMGYIP（A / L）VGAPL，GEVQVVSTATQSFLATCINGVCWTV，HMWNFISGIQYLAGLSTLPGNPA，VDYPYRLWHYPCT（V / I）N（F / Y）TIFK（V / I）RMYVGGVEHRL，AAWYELTPAETTVRLR，GQGWRLLAPITAYSQQTRGLLGCIV，IGLGKVLVDILAGYGAGVAGALVAFK，FTDNSSPPAVPQTFQV，LEDRDRSELSPLLLSTTEW，YLVAYQATVCARAQAPPPSWD，MSTNPKPQRKTKRNTNR，LINTNGSWHINRTALNCNDSL，TTILGIGTVLDQAET，FDS（S / VLCECYDAG（A / C）AWYE，ARLIVFPDLGVRVCEKMALY，AFCSAMYVGDLCGSV，GVLFGLAYFSMVGNW，VVCCSMSYTWTGALITPC，TRVPYFVRAQGLIRA和TTLLFNILGGWVAAQ。